We describe new methods for the detection of immunoglobulin G (IgG) and IgM rubella-specific antibodies in serum. The IgG assay was based on a solid-phase rubella antigen immobilization approach, and the IgM assay was based on the IgM capture assay principle. Both assays used biotinylated antibodies (anti-human IgG and antirubella monoclonal antibody, respectively). The tracer system was based on streptavidin labeled with a fluorescent europium chelate. The final measurements were done by using time-resolved fluorescence. Both assays were thoroughly evaluated with clinical samples and compared successfully with established techniques.
Because of the teratogenic potential of rubella and the limited reliability of clinical diagnosis, rapid laboratory confirmation of rubella infection is often required. For patients who have recently had rubellalike illness, this may be achieved by demonstrating the presence of rubella-specific immunoglobulin M (IgM) in serum. These antibodies, however, persist for only short periods of time and are replaced by higher titers of rubella-specific IgG antibodies. The assay of rubella IgG antibodies in serum is an important test that is used to identify women at risk and as an aid in immunization programs.
Several methods have been proposed to detect IgG and IgM rubella antibodies in serum. The classical hemagglutination inhibition assays (6, (17) (18) (19) and the hemolysis-in-gel assay (3) have been largely replaced by rapid and simple immunological procedures which are based on the following principles. (i) For specific IgG detection, a solid phase is coated with the rubella antigen which binds the specific antibodies from the sample from the patient. The captured antibodies are then detected by reacting them with an anti-human IgG antibody labeled with a tracer such as a radioactive nuclide, an enzyme, or a fluorescent probe (5, 12, 16, 24, 26) . (ii) For specific IgM detection, the so-called IgM capture assay is preferable because of its increased specificity (1, 2, 4, 10, 21; P. Morgan-Capner, J. Hodgson, K. Bellamy, and P. S. Gardner, Eur. Group Rapid Viral Diagn. Newsl. 7:35, 1984) . In this assay, an anti-human IgM antibody is immobilized on a solid phase to capture the IgM antibodies that are present in patient serum. Rubella antigen is then added, along with another rubella antigen-specific antibody which is labeled with a tracer system. The immunocomplex (anti-human IgM-IgM-rubella antigen-anti-rubella-antibody-label) that is formed on the solid phase can then be quantified accordingly.
Recently, a new detection method, time-resolved fluorescence in combination with fluorescent rare earth chelates (and especially europium chelates), has been introduced in the field of nonisotopic immunoassays. This technique has been reviewed recently (7, 14, 23) (15) . The FIAgen system CyberFluor Inc., Toronto, Ontario, Canada) uses the europium chelator 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) as the label (11) . These two systems have recently been compared critically (7) . The DELFIA system has already been used successfully for detecting antigens and antibodies in serum (13, 20, 22) .
In this report, we describe the first application of the FIAgen design for detecting IgG and IgM antibodies to rubella virus in serum. 7 .80] containing 9 g of NaCl, 5 g of bovine serum albumin, 0.5 g of bovine gamma globulin, and 0.1 ml of Tween 40 per liter).
MATERIALS AND METHODS
Procedure for rubella IgG. One hundred microliters of prediluted standard or serum samples (in duplicates) was pipetted into the rubella antigen-coated wells and incubated for 1 h. The strips were then washed four times with the wash solution (0.5 g of Tween 20 and 9 g of NaCl per liter), and 100 ,ul of a 5-mg/liter biotinylated goat anti-human IgG solution (diluted in the assay buffer) was added. This was followed by a 30-min incubation and washing as described above. A total of 100 pi of a diluted tracer solution [SA(BCPDA)14] was then added and incubated for an additional 30 min. All incubations were carried out in a 37°C air oven. After washing, the strips were dried with a stream of cold air for 5 min. Surface fluorescence was measured on the CyberFluor 615 immunoanalyzer. The instrument has an automatic data reduction capability, and results are printed automatically along with the calibration curve as soon as the readings are complete (about 5 min for a 96-well plate). The final immunocomplex on the solid phase is shown diagrammatically in Fig. 1 .
Procedure for rubella IgM. One hundred microliters of prediluted control and patient serum samples was pipetted into the anti-IgM-coated wells and incubated for 1 h at 37°C. The strips were then washed four times, and 100 pi of rubella antigen (diluted 10-fold in the assay buffer) was added. This was followed by overnight ( added, and the assay was completed exactly as described above for the rubella IgG assay.
The final immunocomplex on the solid phase is shown diagrammatically in Fig. 2 10-fold . At this concentration, the ratio of fluorescence of positive and negative sera was maximum.
The assay was performed at various dilutions of serum in buffer. At a 100-fold dilution, sera with low titers (1/10 by latex agglutination) could be easily distinguished from negative sera, and sera with high (1/160) and very high (1/320) titers could be distinguished from each other.
Time courses were done to optimize the assay incubation times. Maximum binding of anti-rubella IgG to the coating antigen was achieved in 1 h, while binding of goat antihuman IgG to the rubella-specific IgG was complete in 30 min (data not shown).
(il) Criteria for positive results. A typical dose-response curve for a rubella IgG assay is shown in Fig. 3 (25) .
(iii) Comparison with other methods. In order to validate the results of the TR-FIA used in this study, it was compared with two commercial enzyme-linked immunoassay kits for anti-rubella IgG and with a latex agglutination assay.
A total of 427 samples were analyzed by the present method and the Rubazyme (Abbott) IgG assay (Fig. 4) . Above 20 IU/ml, the enzyme-linked immunosorbent assay was insensitive to increasing antibody concentration, and the absorbance readings leveled off. Thus, the correlation coefficient was determined only for sera with concentrations of s<20 IU/ml and was found to be 0.94. The diagnostic specificity and sensitivity of the present assay were found to be 96. 8 Seventy-four samples assayed by the method described in this report and by latex agglutination correlated well. These results are shown in Fig. 5 . All samples with titers of <1/10 were negative by the fluorescence assay. All but two samples with titers of 1/10, which is the demarcation titer for immunity to rubella infection, were negative by the TR-FIA. All samples with titers of >1/10 except two, which had titers of 1/20 and 1/40, were found to be positive by TR-FIA. Two of the samples with titers of 1/10 which had results of <5 IU/ml and three of the four samples with positive latex agglutination titers but negative titers by TR-FIA were measured by using a commercial enzyme immunoassay kit. This assay confirmed the negative results.
We investigated the seroconversion in 28 paired serum specimens; 11 pairs were collected before and after patients were given the rubella vaccination, 13 pairs were collected from patients during the acute and convalescent stages of rubella infection, and 4 pairs were collected from patients in the acute and convalescent stage of a disease other than rubella. Seroconversion occurred if there was a fourfold increase in the antibody titer after exposure to rubella antigen. In the 11 paired serum samples taken before and after patients were vaccinated with rubella antigen, all the prevaccination antibody concentrations were under 7 IU/ml and all of the postvaccination concentrations were >24 IU/ml. In each case the antibody concentration ratio after: before vaccination was greater than 4. The results for sera taken from patients in the acute and convalescent stage of rubella infection were similar. In each case there was at least a fourfold increase in the concentration of antirubella antibody. In contrast, in the serum pairs collected from patients with nonrubella disease, the rubella antibody concentrations varied from weakly positive to positive in those with the acute stage of the disease and were unchanged in those in the convalescent stage of the disease. These results are shown in Fig. 6 .
(iv) Assay performance characteristics. The linearity of the assay is demonstrated in Table 2 . Four samples with positive titers of antirubella IgG were serially diluted with negative serum samples. These were diluted 1/100 with buffer and assayed. The correlation coefficient of the observed values to the concentration expected after dilution was 0.98.
The precision of the assay was determined. For withinassay precision, each of three serum specimens (a negative, a low positive, and a high positive specimen) was measured 12 times. The within-run coefficients of variation were 7.7, 6.4, and 4.7%, respectively. Four positive serum samples were analyzed in duplicate for seven or eight times in a 2-week period. The between-run precision varied from 3 to 7.5%. These results are summarized in Table 3 . a Four samples were diluted with a serum sample that had a low concentration of anti-rubella IgG. All the samples were further diluted 100 times in buffer prior to analysis. The correlation coefficient of the observed (y) versus the expected (x) value was 0.98. Rubella IgM assay. (i) Optimization. The antirubella IgM assay was optimized for sample dilution, antigen dilution, and incubation times. The assay was performed at various dilutions of patient serum. At a 100-fold dilution (the dilution used for the IgG assay), it was possible to clearly distinguish a negative and a low positive serum specimen; this was therefore chosen as the working dilution. The precision of the IgM assay was determined. For within-assay precision, each of six serum samples (two negatives, two low positive and two high positive samples) was measured 12 times. The within-run precision (coefficients of variation) varied from 2.9 to 7.9%. The same six serum samples were analyzed in duplicate 8 to 12 times over a period of 2 weeks. The between-run precision varied from 6.7 to 9.3%. These results are summarized in Table 3 .
These results demonstrate that the two antirubella immunoglobulin assays described here are sensitive. They are simple to perform and can accurately determine the immune status of a patient or confirm a diagnosis of rubella infection.
In recent years, solid-phase enzyme immunoassays have replaced the agglutination assays for rubella IgG and IgM. The TR-FIA described here retains the advantages of these solid-phase assays. The serùm was untreated before analysis, although it was diluted. The assays were done in a 96-well microtitration plate format, which lent itself readily to the large batch sizes used in screening assays. In addition, TR-FIA had a very large range of linear response (greater than 3 orders of magnitude). Thus, the linear range of an assay is limited by the antibody system used and not by the detection system. It is proposed that these newly developed assays are suitable for routine use in clinical and microbiological laboratories. 
